tiprankstipranks
Advertisement
Advertisement

Novo Nordisk Discloses Management Share Transfers Under Long-Term Incentive Plan

Story Highlights
  • Novo Nordisk senior leaders received no-cost B shares on 4 February under its long-term incentive scheme.
  • One executive sold part of awarded shares on Nasdaq Copenhagen to cover taxes, in routine, disclosed insider dealing.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Novo Nordisk Discloses Management Share Transfers Under Long-Term Incentive Plan

Claim 55% Off TipRanks

Novo Nordisk ( (NVO) ) has issued an update.

On 4 February 2026, several senior figures at Novo Nordisk, including board member Liselotte Sofie Hyveled, President and CEO Maziar Mike Doustdar, Executive Vice President for US Operations David Moore and Executive Vice President for International Operations Emil Kongshøj Larsen, received transfers of Novo Nordisk B shares at no cost under the company’s long-term incentive programme, in line with EU market abuse regulations on reporting insider dealings. The transactions, some executed outside a trading venue and one sale on Nasdaq Copenhagen by David Moore to cover tax obligations on the incentive shares, underline the continued use of equity-based remuneration to align management with shareholder interests and reflect standard governance and transparency practices rather than a change in strategic direction or capital structure.

The most recent analyst rating on (NVO) stock is a Hold with a $52.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.

The score is driven primarily by strong underlying profitability and solid cash generation, but it is held back by weak price trend/technical setup and a cautious 2026 outlook with pricing and policy-driven headwinds. Valuation and dividend yield provide partial support.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk A/S is a Denmark-based global healthcare company specialising in diabetes care and other serious chronic diseases, with its primary products including insulin and GLP-1 treatments as well as related therapies. Its shares, including the B shares referenced in this filing, are listed on Nasdaq Copenhagen and are widely held by international investors, making insider transactions closely watched by the market.

Average Trading Volume: 21,498,162

Technical Sentiment Signal: Sell

Current Market Cap: $213.7B

Learn more about NVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1